Alume Biosciences has filed a notice of an exempt offering of securities to raise $45,024,930.00 in Equity Investment.
San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Alume Biosciences is raising $45,024,930.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Quyen Nguyen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Alume Biosciences
Loss of nerve function can be catastrophic. As many as 80% of prostate surgeries result in incontinence or erectile dysfunction because of nerve damage, and as many as 25% of head and neck surgeries damage the facial nerves. The mission of Alume Biosciences is to make our proprietary nerve illumination technology available for surgeons so that patients everywhere can benefit. Learn how you can help us move surgery into the light.
To learn more about Alume Biosciences, visit http://alumebiosciences.com/
Contact:
Quyen Nguyen, Chief Executive Officer
858-254-7116
https://www.linkedin.com/in/quyen-nguyen-md-phd-522bb77/
SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved